HGHan Gao

Han Gao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Han Gao has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Helder Almeida Santos

    Department of Biomaterials and Biomedical Technology The Personalized Medicine Research Institute (PRECISION) University Medical Center Groningen University of Groningen Groningen The Netherlands

    2 shared publications
  • Chunxing Yan

    Key Laboratory of Theoretical Organic Chemistry & Functional Molecule, Ministry of Education, Hunan Provincial Key Laboratory of Controllable Preparation & Functional Application of Fine Polymers, School of Chemistry & Chemical Engineering, Hunan University of Science & Technology, Xiangtan, Hunan 411201, PR China

    1 shared publication
  • Claudia Reyes-San-Martin

    Department of Biomaterials and Biomedical Technology The Personalized Medicine Research Institute (PRECISION) University Medical Center Groningen University of Groningen Groningen The Netherlands

    1 shared publication
  • Fei Yang

    Hunan Province Key Laboratory of Typical Environmental Pollution and Health Hazards, School of Public Health, Hengyang Medical School, University of South China, Hengyang 421001, China

    1 shared publication
  • Gésinda Geertsema‐Doornbusch

    Department of Biomaterials and Biomedical Technology The Personalized Medicine Research Institute (PRECISION) University Medical Center Groningen University of Groningen Groningen The Netherlands

    1 shared publication
  • Maria Carmona Lobita

    Department of Biomaterials and Biomedical Technology The Personalized Medicine Research Institute (PRECISION) University Medical Center Groningen University of Groningen Groningen The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Microneedles Mediated Delivery of Nanodiamonds for Quantum Sensing of Free Radicals in Skin Tissue

    by Siyu Fan, Maria Carmona Lobita, Thea Vedelaar, Yue Zhang, Claudia Reyes‐San‐Martin, Tomás Bauleth‐Ramos, Gésinda Geertsema‐Doornbusch, Han Gao, Mohammad‐Ali Shahbazi, Hélder A. Santos, et al.

    Free radicals in the skin are major contributors to the aging process and the development of cancer, making their detection crucial in both research and clinical diagnosis. Real‐time magnetic noise sensing within skin tissues, especially through a quantum sensing technique known as T1 relaxometry, offers a promising approach for monitoring free radical activity. This technique uses fluorescent nanodiamonds (FNDs), whose optical properties change in response to magnetic fluctuations. To effectively deliver FNDs into the epidermis, we developed a dissolving microneedle (DMN) system composed of 10% polyvinylpyrrolidone and 3% hyaluronic acid. The DMNs exhibited strong FND fluorescence intensity concentrated at the microneedle tips (44%), optimizing their deposition within the epidermal layer. Histological analysis confirmed penetration depths of approximately 100–200 µm. To evaluate the sensing performance, T1 relaxometry measurements were conducted using gadolinium chloride solutions at the concentrations of 100 n m and 10 µ m as surrogates for free radicals. Compared to the baseline, the mean T1 values decreased by 35% and 55% for 100 n m and 10 µ m groups, respectively, demonstrating the system's sensitivity. Overall, our results highlight the potential of FND‐loaded DMNs as a minimally invasive platform for high‐resolution monitoring of oxidative stress and related biological processes in skin tissue.

  • Open Access

    Nanoparticle‐mediated siRNA delivery systems for cancer therapy

    by Han Gao, Ruoyu Cheng, Hélder A. Santos

    The small interfering RNA (siRNA)‐based therapeutics have raised great attention since the first RNA interference (RNAi)‐derived drug, patisiran, was approved by the US Food and Drug Administration, which represented a landmark in the field of gene therapy. Given the properties of interfering disease‐associated gene expression, RNAi machinery is regarded as an essential factor for preparing precise medicine. However, over the past few years, siRNA drugs are undergoing a period of clinical translation, in which the major hurdle is the limited efficient delivery strategies. Therefore, this mini‐review mainly focuses on describing the state‐of‐the‐art of the nanoscale platforms for delivering siRNA payloads, also addressing their applications in cancer therapy. Finally, the status of siRNA drugs under clinical trials is discussed, providing a comprehensive understanding on the field of oligonucleotide‐mediated therapeutics.


  • Small-molecule PROTACs: Novel Agents for Cancer Therapy

    by Yichao Wan, Chunxing Yan, Han Gao, Tingting Liu

    Proteolysis-targeting chimera (PROTAC) is a new technology to selectively degrade target proteins via ubiquitin-proteasome system. PROTAC molecules (PROTACs) are a class of heterobifunctional molecules, which contain a ligand targeting the protein of interest, a ligand recruiting an E3 ligase and a linker connecting these two ligands. They provide several advantages over traditional inhibitors in potency, selectivity and drug resistance. Thus, many promising PROTACs have been developed in the recent two decades, especially small-molecule PROTACs. In this review, we briefly introduce the mechanism of PROTACs and focus on the progress of small-molecule PROTACs based on different E3 ligases. In addition, we also introduce the opportunities and challenges of small-molecule PROTACs for cancer therapy.


  • Linc‐ROR regulates apoptosis in esophageal squamous cell carcinoma via modulation of p53 ubiquitination by targeting miR‐204‐5p/MDM2

    by Han Gao, Tian Wang, Peng Zhang, Muhe Shang, Zhikui Gao, Fei Yang, Ran Liu

    The long intergenic noncoding RNA, regulator of reprogramming (linc‐ROR) has been reported to participate in tumorigenesis, while its functions and fundamental mechanisms in esophageal squamous cell carcinoma (ESCC) remain unclear. In this study, gain‐of‐function assays showed that linc‐ROR upregulation enhanced cell viability, promoted cell proliferation, and inhibited apoptosis. Mechanistically, the regulatory network of linc‐ROR/miR‐204‐5p/MDM2 was established with bioinformatics analysis and online databases, then validated via dual‐luciferase reporter assays, RNA immunoprecipitation assays in ESCC cells. Linc‐ROR positively regulates the expression of MDM2 as a molecular sponge of miR‐204‐5p. Moreover, results of western blot and coimmunoprecipitation indicated that linc‐ROR overexpression enhanced the ubiquitination level of p53, and its downstream apoptosis‐related genes have showed higher bcl‐2 expression, lower bax, and cleaved caspase‐3 expressions, while miR‐204‐5p could counteract with this effect. Finally, small interfering RNAs tailored to linc‐ROR were established to further evaluate its effects on ESCC comprehensively. In summary, this study revealed that linc‐ROR modulated cell apoptosis and regulated p53 ubiquitination via targeting miR‐204‐5p/MDM2 axis, which provides a novel therapeutic insight into treatments for ESCC.